 The low efficacy of dentvaxia registered higher risk of severe diseases among dengue naive children and the challenge of developing a vaccine providing balance immunity to all four DENV serotypes have cast skepticism about the safety of dengue vaccination in the Philippines. While tetravalent live attenuated tetravalent vaccines, labs are still favored to approaches for developing a next generation dengue vaccine have emerged inducing potent type specific neutralizing antibodies, NTFs, recognizing quaternary structure dependent epitopes or inducing protective and broadly NTFs against the four serotypes of DENV with a universal vaccine. The article reviews related studies and highlights the knowledge gap that needs to be filled in order to develop an effective dengue vaccine. This article was authored by Jed Hun Yucat Galula, Kilini M. Salem, Guangzhen J. Chong, and others.